Iovance Biotherapeutics (IOVA) has reported third quarter 2026 results, posting revenue of US$121.47 million and a net loss of US$22.27 million, or a basic and diluted loss of US$0.05 per share. The ...
Source LinkIovance Biotherapeutics (IOVA) has reported third quarter 2026 results, posting revenue of US$121.47 million and a net loss of US$22.27 million, or a basic and diluted loss of US$0.05 per share. The ...
Source Link
Comments